20 / 20
Page 45
Notes:
allied
academies
J Med Oncl Ther 2017 | Volume 2 Issue 4
Oncology and Biomarkers Summit
November 27-28, 2017 | Atlanta, USA
Annual Congress on
Development of diagnostic and prognostic biomarkers and understanding the signaling using protein
interaction network in neurodegenerative diseases
Deepshikha Pande Katare
Amity Institute of Biotechnology, India
N
eurodegenerative Diseases (NDs) involve sequentially
interacting pathological cascades, including the interaction
of amyloid-beta aggregation with plaque deposition, Lewy
bodies formation, initiation of seizures, tremor and hyper-
phosphorylation of tau protein with formation of tangles.
Together with associated processes, such as inflammation and
oxidative stress, these pathological cascades contribute to loss
of synaptic integrity and progressive neurodegeneration. Today
the focus is being placed on the discovery of oxidative stress
biomarkers for the understanding of neurological disorders.
Inadequacy in disease detection/treatment and the lack of
diagnostic and prognostic tools have prompted investigators to
turn to proteomics-based biomarker discovery. In the present
study, we have developed animal models using zebrafish
and Wistar rats for multiple NDs. The differential expression
of proteins was analyzed in serum and brain tissue with the
disease progression. The behavior studies and biochemical
analysis confirmed the desired pathology in the animal model.
The differentially expressing proteins were identified and
subjected for further validation in humans for the prospective
diagnostic/prognostic biomarkers. Further characterization of
these proteins will likely shed more light on the mechanisms by
which the changes or modification in these proteins and their
interaction with the other protein in the pathway. The current
study will also contribute to identify the new drug targets for
subsequent therapeutic development and also the link between
the different NDs. This link can also help in understanding the
initiation of all neurological damage.
Speaker Biography
Deepshikha Pande Katare has the research and teaching experience of 21 years and she
has been extensively working in the area of Pharmaceutical/Medical Biotechnology.
She has Master degree in Genetics with Human Genetics specialization and PhD in
Biotechnology. In the past she has worked at NIPER, Mohali, Chandigarh and Hamdard
University, New Delhi for about 10 years. Currently she is working as Professor and
Head Medical Biotechnology in Amity University. The research area is human health
where she is working with collaborators both from India and Abroad as well as PhD
scholars registered under her Supervision from multidiscipline specialization. She has
undertaken various research projects and successfully guided PhD students in the
area of Diagnostic prognostic biomarkers of HCC and Lung cancer and phytosomal
formulations and characterization for epilepsy and Parkinson’s disease. She has around
42 patents and more than 70 publications in the related area.
e:
dpkatare@amity.edu